Priority Review Granted, Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 22, 2026 -- -- Company Plans to Submit the MOLBREEV...
-Financing led by Forbion, joined by Sanofi and existing investors Medicxi, Pitango, and Atlantic Partners- -Proceeds to advance vapendavir, a first-in-...
Merlin CP-GEP is the only molecular test recognized by NCCN as predictive and appropriate for use in select T1 and T2 patients to support shared d...
Sōlaria Biō, a biotechnology company pioneering natural solutions for healthy aging, recently published the findings of a new open-label, randomized cl...
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 14...
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-D...
Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization, announced a defin...
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a hi...
Endoplasmic reticulum (ER) stress and the unfolded protein response are often implicated in the progression of metabolic dysfunction-associated stea...
Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced &nb...
MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years – &nda...
MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative disea...
-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
© 2026 Biopharma Boardroom. All Rights Reserved.
